These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 24797666)
21. Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity. Gradinati V; Baruffaldi F; Abbaraju S; Laudenbach M; Amin R; Gilger B; Velagaleti P; Pravetoni M Vaccine; 2020 Jun; 38(30):4704-4712. PubMed ID: 32439214 [TBL] [Abstract][Full Text] [Related]
22. An Advance in Prescription Opioid Vaccines: Overdose Mortality Reduction and Extraordinary Alteration of Drug Half-Life. Kimishima A; Wenthur CJ; Zhou B; Janda KD ACS Chem Biol; 2017 Jan; 12(1):36-40. PubMed ID: 28103678 [TBL] [Abstract][Full Text] [Related]
23. Adjuvants for vaccines to drugs of abuse and addiction. Alving CR; Matyas GR; Torres O; Jalah R; Beck Z Vaccine; 2014 Sep; 32(42):5382-9. PubMed ID: 25111169 [TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions. Cornish KE; de Villiers SH; Pravetoni M; Pentel PR PLoS One; 2013; 8(12):e82557. PubMed ID: 24312662 [TBL] [Abstract][Full Text] [Related]
25. Developing Translational Vaccines against Heroin and Fentanyl through Investigation of Adjuvants and Stability. Blake S; Bremer PT; Zhou B; Petrovsky N; Smith LC; Hwang CS; Janda KD Mol Pharm; 2021 Jan; 18(1):228-235. PubMed ID: 33301675 [TBL] [Abstract][Full Text] [Related]
26. Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii. Song P; He S; Zhou A; Lv G; Guo J; Zhou J; Han Y; Zhou H; Hao Z; Cong H BMC Infect Dis; 2017 Jan; 17(1):19. PubMed ID: 28056837 [TBL] [Abstract][Full Text] [Related]
27. The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis. McAnally JL; Xu L; Villain M; Blalock JE Exp Biol Med (Maywood); 2001 Apr; 226(4):307-11. PubMed ID: 11368422 [TBL] [Abstract][Full Text] [Related]
28. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001 [TBL] [Abstract][Full Text] [Related]
29. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175 [TBL] [Abstract][Full Text] [Related]
30. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709 [TBL] [Abstract][Full Text] [Related]
31. Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier. Miller KD; Roque R; Clegg CH PLoS One; 2014; 9(12):e114366. PubMed ID: 25494044 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder. Raleigh MD; King SJ; Baruffaldi F; Saykao A; Hamid FA; Winston S; LeSage MG; Pentel PR; Pravetoni M Neuropharmacology; 2021 Sep; 195():108653. PubMed ID: 34126123 [TBL] [Abstract][Full Text] [Related]
33. A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse. Sulima A; Jalah R; Antoline JFG; Torres OB; Imler GH; Deschamps JR; Beck Z; Alving CR; Jacobson AE; Rice KC; Matyas GR J Med Chem; 2018 Jan; 61(1):329-343. PubMed ID: 29236495 [TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Singh M; Li XM; Wang H; McGee JP; Zamb T; Koff W; Wang CY; O'Hagan DT Infect Immun; 1997 May; 65(5):1716-21. PubMed ID: 9125552 [TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of a promiscuous T cell epitope peptide based conjugate vaccine against benzo[a]pyrene: redirecting antibodies to the hapten. Schellenberger MT; Grova N; Farinelle S; Willième S; Revets D; Muller CP PLoS One; 2012; 7(5):e38329. PubMed ID: 22666501 [TBL] [Abstract][Full Text] [Related]
36. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Downham MR; Auton TR; Rosul A; Sharp HL; Sjöström L; Rushton A; Richards JP; Mant TG; Gardiner SM; Bennett T; Glover JF Br J Clin Pharmacol; 2003 Nov; 56(5):505-12. PubMed ID: 14651724 [TBL] [Abstract][Full Text] [Related]
38. A Strong Humoral Immune Response Induced by a Vaccine Formulation Containing rSm29 Adsorbed to Alum Is Associated With Protection Against Alves CC; Araujo N; Bernardes WPOS; Mendes MM; Oliveira SC; Fonseca CT Front Immunol; 2018; 9():2488. PubMed ID: 30450095 [TBL] [Abstract][Full Text] [Related]
39. Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. Laudenbach M; Baruffaldi F; Robinson C; Carter P; Seelig D; Baehr C; Pravetoni M Sci Rep; 2018 Apr; 8(1):5508. PubMed ID: 29615715 [TBL] [Abstract][Full Text] [Related]